Merck & Co.
AWARDS
NEWS
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are life-threatening hospital-related pulmonary infections that can particularly impact patients who are already dealing with severe underlying medical conditions.
Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.
Here’s a look at what’s on the U.S. Food and Drug Administration’s calendar for the next two weeks.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
About 1% of patients treated for cancer with checkpoint inhibitors can develop an autoimmune disease similar to Type 1 diabetes.
Here’s a roundup of some of the top clinical trial news from the previous week.
JOBS
IN THE PRESS